Icon

ALIMTA (nda021462)- (EQ 500MG BASE/VIAL,EQ 100MG BASE/VIAL)

PEMETREXED DISODIUM LILLY
EQ 500MG BASE/VIAL,EQ 100MG BASE/VIAL
Yes No
2022-May-24 Expired
None None
None No
ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery.
17 0 14
Total Other Developers 4
Drugs with Suitability Yes
EQ 500MG BASE/VIAL ** ** - - -
EQ 100MG BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 10
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* **** *** ********* **** ***, *** *********** **** ****** ****, ***** ******, *** **** (**) *****, ****** ****** (***) ***
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ****** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** **** ***** ****** **** ************** (******) **., ***. *********** **.***-*, ****** ******, ******** ****-**** ****, ******, ****** ******, ***** (***) ***
****** ******* ****** ***** ******* ****** ************** ***** **., ***. *** **** *********** **.* ******* ****, ******** *** ********* *********** ****., ***********, ******* ******, ***** (***) ***
****** ******** **** ******** **** ******** ******* ******* *********** ********* ****** **** ******** ******, *-*** *** **** ** ****, , ***** ******* ****, ******,, **** ******, *********** ******, ***** (***) ***
****** ******** **** ******** **** ******** ******* ******* *** *********** ********* ****** **** ******** ******, *-*** *** **** ** ****, , ***** ******* ****, ******,, **** ******, *********** ******, ***** (***) ***
****** ***** ****** ***** ******* ******** ******* ******* *********** **** **.*, *******, ******* ******** ****, ******* ***** *******, ******* ******, ****** ******, *********, ******* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***
****** ****** ****** ******** ******* ******* *********** **** **. *-*, *-*, *-**, *****-*** *******-********* ******-********* *************, *************, ** ******, ***** (***) ***
****** ****** ******** **** ****** ******** **** *********** *********** *, *****/*********, *****, ******* (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.